Trial Profile

Pacritinib Prior to Transplant for Patients With Myeloproliferative Neoplasms (MPN)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Nov 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pacritinib (Primary) ; Busulfan; Fludarabine
Indications Essential thrombocythaemia; Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera
Focus Therapeutic Use

Most Recent Events

10 May 2016 According to CTI BioPharma media release, FDA has removed the clinical hold.
10 May 2016 Status changed from suspended to recruiting, as per CTI BioPharma media release.
08 Feb 2016 According to a CTI BioPharma media release, the US FDA has placed a full clinical hold on the company's IND for pacritinib. Under the full clinical hold, all patients currently on pacritinib must discontinue pacritinib immediately and no patients can be enrolled or start pacritinib as initial or crossover treatment.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com